Technical Trend Overview
Windlas Biotech’s technical trend has transitioned from a clearly bearish stance to a mildly bearish one, signalling a potential stabilisation in price momentum. The stock closed at ₹757.00 on 6 Mar 2026, marginally down by 0.22% from the previous close of ₹758.65. The intraday range was relatively tight, with a low of ₹750.00 and a high of ₹763.10, indicating subdued volatility.
Over the past 52 weeks, the stock has traded between ₹728.15 and ₹1,137.60, highlighting significant price fluctuations within the Pharmaceuticals & Biotechnology sector. This wide range underscores the importance of technical analysis to gauge near-term directional bias.
MACD Signals: Divergent Weekly and Monthly Perspectives
The Moving Average Convergence Divergence (MACD) indicator presents a mixed scenario. On the weekly chart, the MACD is mildly bullish, suggesting that short-term momentum may be improving. This is a positive sign for traders looking for potential upward price movement in the near term.
Conversely, the monthly MACD remains mildly bearish, indicating that the longer-term trend has yet to confirm a sustained recovery. This divergence between weekly and monthly MACD readings suggests that while short-term buying interest is emerging, the broader downtrend has not been decisively reversed.
RSI and Bollinger Bands: Neutral to Bearish Signals
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no definitive signal, hovering in neutral territory. This implies that the stock is neither overbought nor oversold, leaving room for either a continuation of the current trend or a reversal depending on upcoming market catalysts.
Bollinger Bands, however, indicate a mildly bearish stance on both weekly and monthly timeframes. The stock price is closer to the lower band, which often signals increased selling pressure or a potential oversold condition. Investors should watch for any price action that breaks below or rebounds from these bands to anticipate future volatility.
Moving Averages and KST: Daily Bearish, Weekly Mixed
Daily moving averages remain bearish, reinforcing the short-term downtrend. This is consistent with the stock’s recent price weakness and suggests that immediate resistance levels may cap any rallies.
Meanwhile, the Know Sure Thing (KST) indicator shows a mildly bullish signal on the weekly chart but remains mildly bearish on the monthly chart. This further emphasises the conflicting momentum signals across different time horizons, complicating the outlook for traders and investors alike.
Transformation in full progress! This Micro Cap from Auto Ancillary just achieved sustainable profitability after tough times. Be early to witness this powerful comeback story!
- - Sustainable profitability reached
- - Post-turnaround strength
- - Comeback story unfolding
Volume and Dow Theory: Predominantly Bearish Signals
On-Balance Volume (OBV) analysis reveals a mildly bearish trend on the weekly chart, indicating that volume flow is not strongly supporting upward price moves. The monthly OBV shows no clear trend, suggesting indecision among market participants over the longer term.
Dow Theory assessments align with this cautious stance, with both weekly and monthly readings mildly bearish. This reinforces the notion that the stock remains under selling pressure, despite intermittent short-term rallies.
Comparative Returns: Underperformance Against Sensex
Windlas Biotech’s recent returns have lagged behind the benchmark Sensex index. Over the past week, the stock declined by 0.61%, while the Sensex fell by a sharper 2.71%. However, over the last month, Windlas Biotech’s loss of 9.55% significantly outpaced the Sensex’s 3.96% decline.
Year-to-date, the stock is down 4.79%, slightly outperforming the Sensex’s 6.11% drop. Over the past year, Windlas Biotech has underperformed considerably, with a 15.03% loss compared to the Sensex’s 8.53% gain. Despite this, the stock boasts an impressive three-year return of 201.11%, far exceeding the Sensex’s 33.79% gain, reflecting strong long-term growth potential.
Mojo Score and Grade Downgrade
MarketsMOJO assigns Windlas Biotech a Mojo Score of 40.0, categorising it with a Sell grade as of 4 Feb 2026, downgraded from Hold. This reflects a cautious stance based on the company’s current fundamentals and technical outlook. The Market Cap Grade stands at 3, indicating a mid-tier valuation relative to peers in the Pharmaceuticals & Biotechnology sector.
Holding Windlas Biotech Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Investor Takeaway: Navigating Mixed Signals
Windlas Biotech’s technical indicators paint a picture of a stock at a crossroads. The mildly bullish weekly MACD and KST suggest some short-term upside potential, but the prevailing bearish monthly indicators and daily moving averages caution against aggressive bullish bets.
Investors should closely monitor price action around key support levels near ₹728 and resistance near ₹763, as well as any shifts in volume patterns that could confirm a trend reversal or continuation. The neutral RSI readings imply that the stock is not currently overextended, leaving room for either a rebound or further decline depending on broader market conditions and sector developments.
Given the downgrade in Mojo Grade and the mixed technical signals, a prudent approach would be to await clearer confirmation of trend direction before increasing exposure. Long-term investors may find value in the stock’s strong three-year performance, but short-term traders should exercise caution amid the current technical ambiguity.
Sector Context and Market Environment
The Pharmaceuticals & Biotechnology sector continues to face headwinds from regulatory uncertainties and competitive pressures, which have contributed to the cautious technical outlook for Windlas Biotech. However, the company’s ability to maintain a market cap grade of 3 and its historical outperformance over three years indicate underlying resilience.
Comparing Windlas Biotech’s technical profile with sector peers may provide additional insights into relative strength and potential opportunities for portfolio rebalancing.
Conclusion
Windlas Biotech Ltd’s recent technical parameter changes highlight a subtle shift in momentum that warrants close attention. While short-term indicators hint at mild bullishness, the dominant monthly and daily bearish signals suggest that the stock remains vulnerable to downside risks. Investors should balance these mixed signals with fundamental analysis and sector trends to make informed decisions.
Continued monitoring of MACD crossovers, moving average behaviour, and volume trends will be critical in assessing whether Windlas Biotech can break free from its mildly bearish phase and resume a more robust uptrend.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
